Filing Flows › Arcutis Biotherapeutics (ARQT) › Q3 2026 › vs Q3 2025
Arcutis Biotherapeutics (ARQT) Q3 2026 vs Q3 2025 (year over year)
Arcutis Biotherapeutics's revenue rose $44.7M (+45%) from $99.2M in Q3 2025 to $144M in Q3 2026. The biggest changes: ZORYVE foam +$25.4M (+51%); ZORYVE cream 0.15% +$8.3M (+44%); ZORYVE cream 0.3% +$7.3M (+24%). Operating margin 6.6% against 8.6% (-2.0 pts).
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 6.6% | 8.6% | -2.0 pts |
| Net margin | 6.1% | 7.5% | -1.4 pts |
| Free cash flow margin | 13.1% | -1.8% | +14.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| ZORYVE foam | $75.1M | $49.8M | $25.4M | +51% |
| ZORYVE cream 0.3% | $37.8M | $30.5M | $7.3M | +24% |
| ZORYVE cream 0.15% | $27.3M | $18.9M | $8.3M | +44% |
| ZORYVE cream 0.05% | $3.7M | $0 | $3.7M | — |
| Revenue | $144M | $99.2M | $44.7M | +45% |
| Operating profit | $9.4M | $8.5M | $910K | +11% |
| Costs & expenses | $134M | $90.7M | $43.8M | +48% |
| Pre-tax earnings | $9.0M | $7.5M | $1.5M | +20% |
| Other expense, net | $440K | $1.0M | −$596K | -58% |
| Cost of revenue | $12.5M | $8.7M | $3.8M | +43% |
| Research & development | $22.4M | $19.6M | $2.8M | +14% |
| SG&A | $99.6M | $62.4M | $37.2M | +60% |
| Net earnings | $8.8M | $7.4M | $1.4M | +19% |
| Income tax | $195K | $80K | $115K | +144% |
| Share-based compensation | $12.4M | $10.0M | $2.3M | +23% |
| Working capital & other | $2.3M | $19.2M | −$16.9M | -88% |
| Operating cash flow | $18.9M | −$1.8M | $20.7M | — |
| Free cash flow (OCF − capex) | $18.8M | −$1.8M | $20.6M | — |
| Capital expenditures | $97K | $0 | $97K | — |
Questions
How much did Arcutis Biotherapeutics's revenue grow year over year in Q3 2026?
Arcutis Biotherapeutics's revenue rose $44.7M (+45%) from $99.2M in Q3 2025 to $144M in Q3 2026.
What drove Arcutis Biotherapeutics's revenue change in Q3 2026?
ZORYVE foam +$25.4M (+51%); ZORYVE cream 0.15% +$8.3M (+44%); ZORYVE cream 0.3% +$7.3M (+24%).